Click on image to view larger version.

Figure 1 Schematic representation of the distribution of the occurrence of contrast agent-associated nephrotoxicity in patients treated with the N-acetylcysteine (NAC group) and with fenoldopam mesylate (fenoldopam group). Filled areas = cases with event; open areas = cases without event.